RxDoctor Payments Data

Raphael Bonita, MD

Cardiovascular Disease · Philadelphia, PANPI 1790973147

Payments from drug & device makers

$2,735in general payments, 2019–2025

Across 51 payments — averaging $53.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Impulse Dynamics (USA) Inc.$1K
  • ZOLL Medical Corporation$356
  • BD$350
  • Abiomed$133
  • Abbott$116
  • Alnylam Pharmaceuticals Inc.$114
  • plus $409 from 12 others

What the payments were for

  • Consulting fees$1,20644%
  • Food & beverage$1,37150%
  • Education$1576%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,735 in reported general payments places this provider in the 60th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$87,730
Medicare patients
357
Services billed
1,123

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan228$270,910
EliquisApixaban193$187,970
FarxigaDapagliflozin Propanediol169$168,532
JardianceEmpagliflozin101$88,816
BrilintaTicagrelor46$33,529
XareltoRivaroxaban24$26,392
JanuviaSitagliptin Phosphate14$7,598
Metoprolol Succinate286$5,169
Atorvastatin Calcium274$4,041
Bumetanide82$3,629
Rosuvastatin Calcium123$2,731
Ezetimibe70$2,133
Icosapent Ethyl17$2,013
Hydralazine Hcl159$1,930
Nifedipine ErNifedipine77$1,857

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$85$270,910228 claims
AstraZenecaFarxiga, Brilinta$17$202,061215 claims
PfizerEliquis$12$187,970193 claims
Boehringer IngelheimJardiance$50$88,816101 claims
MerckJanuvia$88$7,59814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →